Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Wilmen

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Chromosoma|April 1, 1996
The chromatin of the Saccharomyces cerevisiae centromere shows cell-type specific changesA Wilmen, J H Hegemann
FEBS Letters|November 25, 1996
The isolated N-terminal extracellular domain of the glucagon-like peptide-1 (GLP)-1 receptor has intrinsic binding activityA Wilmen, B Göke, R Göke
Peptides|January 1, 1996
Exchange of W39 by A within the N-terminal extracellular domain of the GLP-1 receptor results in a loss of receptor functionB Van Eyll, B Göke, A Wilmen, et al.
Peptides|January 1, 1997
Five out of six tryptophan residues in the N-terminal extracellular domain of the rat GLP-1 receptor are essential for its ability to bind GLP-1A Wilmen, B Van Eyll, B Göke, et al.
Nucleic Acids Research|October 11, 1993
Cpf1 protein induced bending of yeast centromere DNA element IR K Niedenthal, M Sen-Gupta, A Wilmen, et al.
Nucleic Acids Research|July 25, 1994
The yeast centromere CDEI/Cpf1 complex: differences between in vitro binding and in vivo functionA Wilmen, H Pick, R K Niedenthal, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 6, 2001
Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitisB Hilliard, A Wilmen, C Seidel, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|October 29, 1998
The genomic organization of the human GLP-1 receptor geneA Wilmen, A Walkenbach, P Füller, et al.
Journal of Thrombosis and Haemostasis : JTH|March 8, 2005
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitorE Perzborn, J Strassburger, A Wilmen, et al.
The Journal of Experimental Medicine|April 5, 2000
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progressionK Song, Y Chen, R Göke, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Chromosoma|April 1, 1996
The chromatin of the Saccharomyces cerevisiae centromere shows cell-type specific changesA Wilmen, J H Hegemann
FEBS Letters|November 25, 1996
The isolated N-terminal extracellular domain of the glucagon-like peptide-1 (GLP)-1 receptor has intrinsic binding activityA Wilmen, B Göke, R Göke
Peptides|January 1, 1996
Exchange of W39 by A within the N-terminal extracellular domain of the GLP-1 receptor results in a loss of receptor functionB Van Eyll, B Göke, A Wilmen, et al.
Peptides|January 1, 1997
Five out of six tryptophan residues in the N-terminal extracellular domain of the rat GLP-1 receptor are essential for its ability to bind GLP-1A Wilmen, B Van Eyll, B Göke, et al.
Nucleic Acids Research|October 11, 1993
Cpf1 protein induced bending of yeast centromere DNA element IR K Niedenthal, M Sen-Gupta, A Wilmen, et al.
Nucleic Acids Research|July 25, 1994
The yeast centromere CDEI/Cpf1 complex: differences between in vitro binding and in vivo functionA Wilmen, H Pick, R K Niedenthal, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 6, 2001
Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitisB Hilliard, A Wilmen, C Seidel, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|October 29, 1998
The genomic organization of the human GLP-1 receptor geneA Wilmen, A Walkenbach, P Füller, et al.
Journal of Thrombosis and Haemostasis : JTH|March 8, 2005
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitorE Perzborn, J Strassburger, A Wilmen, et al.
The Journal of Experimental Medicine|April 5, 2000
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progressionK Song, Y Chen, R Göke, et al.
Pageof 1